Sequential designs for individualized dosing in phase I cancer clinical trials.

Abstract excerpt

This paper addresses dose finding in clinical trials where individuals exhibit biologic characteristics that alter the toxicity risks of the individuals. In these situations, instead of determining a dose that works for every patient, the trial aims to identify a dosing algorithm that prescribes dose according to the patient's biomarker or pharmacokinetic expression. Specifically, we aim to dose patients around a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Algorithms
• Share to Antineoplastic Agents
• Share to Area Under Curve